INTERVIEW: Finding Stars And Staying Independent, Biotech Veteran David Chiswell's Five Year Plan

David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.

Red pencil

Kymab Ltd. CEO Dr David Chiswell OBE has more than 30 years of experience in the biotechnology industry, having co-founded Cambridge Antibody Technology Group PLC in 1990, a company that originated one of the world’s biggest selling drugs, Humira (adalimumab). CAT was sold to AstraZeneca PLC in 2006 for £702m, and it now forms an important part of its biopharmaceutical franchise.

Since leaving CAT in 2002, he has focused on the development of early-stage biotechnology companies, having previously served as a...

More from Leadership

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?